Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease
- PMID: 32928916
- DOI: 10.1136/gutjnl-2020-322646
Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease
Keywords: Crohn's disease; azathioprine.
Conflict of interest statement
Competing interests: BV reports financial support for research from Pfizer; lecture fees from Abbvie, Ferring, Takeda Pharmaceuticals, Janssen and R Biopharm; consultancy fees from Janssen and Sandoz. JS reports lecture fees from Abbvie, Takeda, Janssen and Nestle Health Sciences. SV reports financial support for research: MSD, AbbVie, Takeda, Pfizer, J&J; Lecture fee(s): MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche; Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Shire, Prodigest, Gilead, Galapagos. MF reports financial support for research: Amgen, Biogen, Janssen, Pfizer, Takeda, Consultancy: Abbvie, Boehringer-Ingelheim, MSD, Pfizer, Sandoz, Takeda and Thermo Fisher; Speakers fee: Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, and Takeda.
Comment in
-
There is still a place for optimised thiopurine therapy in IBD.Gut. 2021 Nov;70(11):2207. doi: 10.1136/gutjnl-2020-323481. Epub 2020 Nov 25. Gut. 2021. PMID: 33239341 No abstract available.
Comment on
-
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.Gut. 2021 Apr;70(4):677-686. doi: 10.1136/gutjnl-2019-320185. Epub 2020 Oct 1. Gut. 2021. PMID: 33004550 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
